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Aberrant expression of miR-1 has been implicated in various cancers. However, the mechanisms underlying the role
of miR-1 in CRC progression still have not been clarified clearly. Here, we showed the decreased expression of miR-1 in
colorectal carcinoma (CRC) tissues and cell lines. Ectopic introduction of miR-1 suppressed cell proliferation and migration,
whereas miR-1 inhibitor performed contrary functions in CRC cells. Stable overexpression of miR-1 was sufficient to inhibit
tumor growth and homing capacity in vivo. Proteomic analysis revealed that miR-1 modulated the expression of
key cellular molecules and involved in the MAPK and PI3K/AKT pathways by inhibiting phosphorylation of ERK
and AKT. Meanwhile, miR-1 also reversed epithelial–mesenchymal transition (EMT), which played a pivotal role in
the initiation of metastasis. Further studies found that miR-1 can target the 3' untranslated region (3'UTR) of LIM
and SH3 protein 1 (LASP1) mRNA and suppress the expression of LASP1, identified as a CRC-associated protein. In
contrast to the phenotypes induced by miR-1 restoration, LASP1-induced cell proliferation and migration partly
rescued miR-1-mediated biological behaviors. Our results illustrated that miR-1 play a critical role in CRC progression,
which suggests its potential role in the molecular therapy of cancer.
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Gene therapyIntroduction
Colorectal cancer (CRC) is one of the most common di-
gestive malignancies and the leading cause of cancer
death in the world. In China, the incidence of CRC still
continues to increase. Despite improvement in the treat-
ment of CRC in the past decade, the overall survival of
patients with CRC has not changed obviously. Metastasis
is the main cause of mortalities and poor outcome [1,2].
The underlying molecular mechanisms in CRC metasta-
sis are still unclear. Hence, it is urgent to explore key
molecules in tumor progression, which may be used to* Correspondence: liangsmu@gmail.com
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MicroRNAs (miRNAs) are a class of diverse, small,
noncoding RNAs that are processed from precursors
with a characteristic hairpin secondary structure [3].
They commonly function as critical gene regulators. In
recent years, a large number of studies have confirmed
that miRNAs are involved in tumorigenesis and metasta-
sis by targeting various types of mRNAs [4]. To date,
dysregulated expression of several miRNAs, such as
miR-21 [5], miR-124 [6], miR-625 [7], miR-339-5p [8]
and miR-27b [9], has been demonstrated to contribute
to development and progression of CRC. In our recent
study, miR-133a was identified as a tumor-suppressive
factor in human CRC that acts by repressing tumor
metastasis-associated protein LIM and SH3 protein 1
(LASP1) [10], which provides additional evidence of a
pivotal role for miRNAs in CRC progression [11].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ulated and repress tumor progression in hepatocellular
[12], prostate [13,14], thyroid [15], bladder [16] and
renal [17]cancer. In colorectal cancer, an experimental
approach, called miRNA serial analysis of gene expres-
sion (miRAGE), was used to perform the largest experi-
mental analysis of human miRNAs. The data showed that
miR-1 was down-regulation in CRC tissues with up to
11.8-fold decrease, compared with control samples [18].
Meanwhile, genome-wide profiling of chromatin signa-
tures reveals epigenetic regulation of microRNA genes,
and showed that miR-1 was methylated frequently in early
and advanced colorectal cancer in which it may act as a
tumor suppressor [19]. A recent study in vitro identified
that concomitant downregulation of miR-1 and increase of
metastasis-associated in colon cancer 1 (MACC1) can con-
tribute to MET overexpression and to the metastatic behav-
ior of colon cancer cells [20]. However, the in vivo function
and underlying mechanism of miR-1 in CRC still have not
been clarified clearly.
In this study, we detected miR-1 expression in CRC
cells and tissue samples. Gain- or loss-of-function assays
were performed to analyze the effect of miR-1 on tumor
cell phenotypes. We established xenograft mice models
to investigate its therapeutic role in vivo. Finally, we also
explored the molecular mechanisms underlying the sup-
pressive function of miR-1 and its potential targets.
Materials and methods
Cell culture and miRNA transfection
CRC cell lines HT29, HCT116, SW480, and SW620 were
purchased from the American Type Culture Collection
(ATCC; Manassas, Va) and maintained as previously de-
scribed [10]. Additionally, a human CRC cell subline with
unique liver metastatic potential, designated SW480/M5,
was established in our laboratory [21] and used in the
analysis. The cells were cultured in RPMI 1640 (Hyclone;
Logan, Utah, USA) supplemented with 10% fetal bovine
serum (FBS) (Gibco-BRL, Invitrogen; Paisley, UK) at a hu-
midity of 5% CO2 at 37°C.
miRNAs were transfected at a working concentration of
100 nmol/L using Lipofectamine 2000 reagent (Invitrogen;
Carlsbad, Calif, USA). The miR-1 mimic, a nonspecific miR
control, anti-miR-1 (miR-1 inhibitor), and a nonspecific
anti-miR control were all purchased from GenePharma
(Shanghai, China). Protein and RNA samples were ex-
tracted from subconfluent cells during the exponential
phase of growth.
Tumor tissue sample
Fresh primary CRC specimens and paired noncancerous
colorectal tissue were provided by the Tumor Tissue
Bank of Nanfang Hospital. In each case, a diagnosis of
primary CRC had been made, and the patient hadundergone elective surgery for CRC in Nanfang Hospital
between 2007 and 2010. The pathological diagnosis was
made in the Department of Pathology of Nanfang Hospital
of Southern Medical University. The study was approved
by the Ethics Committee of Southern Medical University
and all aspects of the study comply with the Declaration
of Helsinki.
RNA isolation, reverse transcription, and quantitative
real-time PCR
See Additional file 1 (available online only) for details.
Western blot analysis
Protein expression was assessed by immunoblot analysis
of cell lysates (20–60 μg) in RIPA buffer in the presence
of mouse antibodies to LIM and SH3 protein 1 (LASP1)
(1:2000; Chemicon, Temecula, CA); E-cadherin, fibronectin
(FN), β-actin (1:500; Santa Cruz, California, USA); rabbit
antibodies to p-Akt (Ser473), p-Akt (Thr308), AKT, p44/42
MAPK (ERK1/2), p-p44/42 MAPK (ERK1/2), Rho GDP-
dissociation inhibitor 1 (ARHGDIA) (1:1000; CST, Danvers,
MA) and transgelin (TAGLN) (1:500; Abcam, Cambridge,
UK).
Cell proliferation assays
See Additional file 1 (available online only) for details.
Cell migration analysis
See Additional file 1 (available online only) for details.
Preparation of lentiviral vectors
A DNA fragment corresponding to pre–miR-1 and the
flanking sequence was amplified from human genomic
DNA and then cloned into pGLV3/H1/GFP + puro lenti-
viral vector (http://www.genepharma.com). The produc-
tion, purification, and titration of lentivirus were performed
as described by Liu and colleagues [22]. The packaged lenti-
viruses were named LV-miR-1. The empty lentiviral vector
LV-con was used as a control.
Tumor growth assay
See Additional file 1 (available online only) for details.
Tumor metastasis assays
See Additional file 1 (available online only) for details.
Proteomic analysis
See Additional file 1 (available online only) for details.
Bioinformatics
Potential miRNA targets were predicted and analyzed
using 3 publicly available algorithms: PicTar, TargetScan,
and miRanda [23]. The number of false-positive results
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that were predicted by at least 2 programs.
miRNA target validation
A 2992-bp fragment of the LASP1 3’ untranslated region
(3’UTR) was amplified by PCR and cloned downstream
of the firefly luciferase gene in the psiCHECK-2 vector
(Promega; Madison, Wis, USA). This vector was named
wild-type (wt) 3’UTR. Site-directed mutagenesis of the
miR-1 binding site in the LASP1 3’UTR was carried out
using the GeneTailor Site-Directed Mutagenesis System
(Invitrogen) and named mutant (mt) 3’UTR. For reporter
assays, the wt or mt 3’UTR vector and miR-1 mimic or in-
hibitor were cotransfected. Luciferase activity was mea-
sured 48 h after transfection using the Dual-Luciferase
Reporter Assay System (Promega, Madison, Wis, USA).
Statistical analysis
Data were analyzed using SPSS version 13.0 software
(SPSS; Chicago, Ill, USA). The Student t-test and the
one-way ANOVA test were carried out for qRT-PCR
and CCK-8 analyses and to calculate the tumor growth
curve. The correlation between miR-1 and LASP1 was
determined using the Spearman rank correlation test.
Statistical significance was established at P < 0.05.Figure 1 The expression of miR-1 was decreased in CRC tissues and c
miR-1 in cancerous versus non-cancerous tissue using qRT-PCR. (B) The mi
match-normal tissues. nmCRC denotes CRC tissues without metastases; mC
miR-1 in five CRC cell lines (SW480, SW620, HCT116, SW480/M5, and HT29) w
miR-1 in 24 non-cancerous tissue samples (N-tissue).Results
Decreased expression of miR-1 in CRC tissues and cell lines
Real-time PCR were used to detect miR-1 expression in
24 CRC tissue and matched adjacent non-cancerous tis-
sue. Down-regulation of miR-1 expression was found in
20 of all the CRC samples, with up to 9.8-fold decrease,
compared with control samples (Figure 1A). The expres-
sion of miR-1 were significantly decreased in CRC tissues
than control samples (P = 0.0016; Figure 1B). A relatively
lower level was found in metastatic CRC (mCRC) com-
pared with non-metastatic CRC (nmCRC) (P = 0.0073;
Figure 1B). In addition, lower expression of miR-1 was
found in all five CRC cell lines compared with the mean
level of the non-cancerous tissue specimens. In consistent
with the data of Figure 1B, a higher expression of miR-1
was found in SW620 and SW480/M5 cells with higher
metastasis potential compared with SW480, HCT116 and
HT29 cells derived from the primary tumors (Figure 1C).
Exogenous miR-1 suppressed CRC cell proliferation and
migration in vitro
We transfected the CRC cell lines SW480 and SW620 with
miR-1 mimic and evaluated the effects on cellular beha-
viors. Real-time PCR were performed to detect the trans-
fection efficiency (P < 0.05; Additional file 2: Figure S1).ell lines. (A) The histogram indicates the differential expression of
R-1 expression in CRC tissues with or without metastases relative to
RC denotes CRC tissues with metastases. (C) The relative expression of
as significantly decreased compared with the mean rate of expression of
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erative ability of miR-1-transfected SW480 and SW620
cells, respectively (P < 0.05; Figure 2A). Transwell assays
showed that miR-1 significantly decreased the potential of
cell migration in SW480 and SW620 (P < 0.05; Figure 2B).
On the contrary, anti-miR-1, as a miRNA inhibitor,
was used to investigate the role of miR-1 depletion in
CRC cell lines SW480 and HCT116. On the contrary
with the above results, we found a significant increase in
the ability of cell proliferation in SW480 and HCT116,
respectively (P < 0.05; Figure 2C). Introduction of anti-
miR also enhanced the number of invaded cells after
transfection with miR-1 inhibitor (P < 0.05; Figure 2D).
These findings suggest miR-1 as a suppressor inhibits
aggressive phenotype of CRC cells.
Endogenous overexpression of miR-1 inhibited CRC
growth and metastasis in vivo
We infected SW480 cells with LV-miR-1 and then estab-
lished SW480/miR-1 cell line with stable miR-1 overexpres-
sion. A qRT-PCR assay confirmed up-regulated 208-fold of
miR-1 expression in SW480/miR-1 cells compared with
SW480/miR-NC cells (Figure 3A). In vitro assay showed
that stable overexpression of miR-1 obviously decreased the
potential of cell growth and migration (Figure 3B-C). Then,
a subcutaneous tumor model was used to evaluate the ef-
fect of miR-1 on tumorigenesis of CRC cells. As shown in
Figure 3D, the tumors in the SW480/miR-1 group grew
more slowly than these in the SW480/miR-NC group, andFigure 2 Ectopic expression of miR-1 inhibited aggressive phenotypes
by CCK-8 assay after miR-1 transfection of SW480 and SW620 cells. (B) Data o
under a microscope in five randomly selected fields. Bars represent the n
anti-miR-1 on cell proliferation was evaluated by CCK-8 assay after anti-m
assay for SW480 and HCT116 cells. The cells were counted under a micro
cells invaded after transfection with anti-miR-1.showed significantly lower Ki-67 index compared with con-
trol (Figure 3E-H).
To analyze the relationship between the potential of
homing capacity and miR-1 expression, we observed liver
and lung nodules after injection of tumor cells via spleen
and tail vein, respectively. Compared with SW480/miR-1
group, we found significantly more and larger tumor nod-
ules in the liver and lung of SW480/miR-NC group, indi-
cating that miR-1 inhibited the homing capacity of CRC
cells (Figure 3I-J).
miR-1 changed protein expression pattern of CRC cells
To reveal the underlying molecular mechanisms of bio-
logical behaviors mediated by miR-1, we performed two
dimensional differential gel electrophoresis (2D-DIGE)
based proteomics strategy to exhibit differential expres-
sion protein profiling after transfection with miR-1 in
SW480 cells (Figure 4A). Using software analysis, 33 dif-
ferential protein spots were found. Among of them, total
31 protein spots were successfully identified by matrix-
assisted laser desorption/ ionization tandem time of flight
mass spectrometry (MALDI-TOF/TOF MS) (Figure 4B;
Additional file 3: Table S1). Two candidate proteins, iden-
tified as Rho GDP-dissociation inhibitor 1 (ARHGDIA)
and transgelin (TAGLN), was confirmed by western blot
analysis, suggesting that the results of proteomic analysis
are convincing (Figure 4E).
We next explore the biological processes involved in
proteins modulated by miR-1 using Gene Ontology.in CRC cells. (A) The effect of miR-1 on cell proliferation was evaluated
f transwell assay for SW480 and SW620 cells. The cells were counted
umber of cells invaded after transfection with miR-1. (C) The effect of
iR-1 transfection of SW480 and HCT116 cells. (D) Data of transwell
scope in five randomly selected fields. Bars represent the number of
Figure 3 miR-1 inhibited tumor growth and metastasis in nude mice. (A) The histogram indicates the increased expression of miR-1 in SW480 cells
with miR-1 overexpression using qRT-PCR. (B) Cell proliferation was evaluated by CCK-8 assay between SW480/miR-1, which has stable overexpression of
miR-1 and control SW480/miR-NC cells. (C) Representative figures and data of transwell assay for SW480/miR-1 and SW480/NC cells. Each bar represents
the mean ± SD. The results were reproduced in three independent experiments. (D) Tumor cells were injected subcutaneously into the back of nude
mice to evaluate cancerogenesis. Representative figure of tumors formed. (E) Tumor volume in the back of nude mice injected with SW480/miR-1 and
SW480/NC cells was measured. The data of all primary tumors are expressed as mean ± SD. (F) Scatter plots of tumor volume derived from SW480/miR-1
and SW480/NC cells at 30 d after subcutaneous implantation. (G) Scatter plots of tumor weight derived from SW480/miR-1 and SW480/NC cells at 30 d
after subcutaneous implantation. (H) Representative photographs of haematoxylin and eosin (H & E) and immunohistochemical staining of primary
cancer tissues were shown (×400). N, necrotic lesion. (I) Number of liver and lung nodules per mice. The number of tumor nodules in individual mice
was counted under the microscope. (J) Tumour cells were injected into nude mice through the spleen and tail vein to evaluate the lung and liver
homing capacity of cells, respectively (H & E staining, ×200). The yellow crosses indicated tumor nodules in the liver and lung. T, tumor lesions.
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biological processes, such as development, response to
stimulus, localization and metabolism, et al. (Figure 4C).
Molecular function annotation indicated that miR-1 mayparticipate in cell signal transduction, regulation of gene ex-
pression and cytoskeleton reorganization, et al. (Figure 4D).
This suggests that miR-1 may play an important role in
tumor progression through diverse mechanisms.
Figure 4 miR-1 altered global protein expression profiles and involved in several key biological processes. (A) 2-D DIGE images of
SW480 cells transfected with miR-1 are shown. Proteins from cells transfected with control were labelled with Cy5. Proteins from cells transfected
with miR-1 were labelled with Cy3. Internal standard proteins were labelled with Cy2. (B) Distribution of differentially expressed protein spots in
merged images of the Cy-dye labelled images is shown. (C) Diagrammatic sketch showed major molecular functions exerted by miR-1 using
Gene Ontology. (D) The histogram indicated main biological processes involved in miR-1 using Gene Ontology. (E) Both enlarged DIGE images
and immunoblotting results of two candidate protein, identified as ARHGDIA and TAGLN, are shown.
Xu et al. Journal of Translational Medicine 2014, 12:244 Page 6 of 12
http://www.translational-medicine.com/content/12/1/244miR-1 mediated inhibition of epithelial-mesenchymal
transition (EMT) and inactivation of signal transduction
pathway
EMT is an critical process during tumor metastasis by
which epithelial cells acquire mesenchymal properties and
show reduced intercellular adhesion and increased motility
[24]. Because we have observed miR-1-mediated reduction
of migration ability and gene expression regulation, we
asked whether miR-1 introduction have an impact on the
expression of EMT-associated proteins. Western blot as-
says showed that exogenous miR-1 resulted in increase ofepithelial markers E-cadherin and decrease of mesenchy-
mal marker fibronectin (FN) (Figure 5A). Using immuno-
fluorescence (IF) assay, we observed an epithelial-like
changes and increased expression of E-cadherin in SW480
cells after treatment with miR-1 (Figure 5B).
Further, we carried out western blot analysis of the
phosphorylation status of proteins involved in EMT sig-
naling. As shown in Figure 5C, miR-1 significantly inhib-
ited mitogen-activated protein kinases (MAPK) pathway
through dephosphorylation of p44/42 MAPK (ERK1/2)
and phosphatidylinositol 3-kinase (PI3K)/AKT signaling
Figure 5 (See legend on next page.)
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Figure 5 miR-1 inhibited EMT and suppressed phosphorylation of ERK and AKT. (A) Western blot analysis was performed to detect the
expression of epithelial cell marker E-cadherin and mesenchymal markers FN in SW480 cells transfected with miR-1. (B) The light microscopy was
used to observe the change of cell morphology in SW480 cells after treatment with miR-1. The immunofluorescence (IF) assay was used to detect
the expression of E-cadherin. (C) Phosphorylation levels of ERK and AKT were detected in SW480, HCT116 and SW620 cells transfected with miR-1
or anti-miR-1. (D) The immunosignal was quantified using densitometric scanning software, and relative protein abundance was determined by
normalisation with total levels of ERK and AKT, respectively.
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Thr308 in SW480 and SW620 cells. On the contrary,
anti-miR-1 activated MAPK and PI3K/AKT pathways
via phosphorylation of ERK1/2 and AKT.
miR-1 directly targets tumor metastasis related gene
LASP1 in CRC cells
Using a bioinformatic analysis (based on TargetScan Hu-
man 6.2, PicTar and miRanda), LIM and SH3 protein 1
(LASP1), identified previously as a CRC metastasis re-
lated gene, was predicted as a possible target of miR-1.
Luciferase reporter assay was performed to determine
whether miR-1 can directly target the 3’UTR region of
Lasp1. This involved in cloning the target sequence (wt
3’UTR) or mutant sequence (mt 3’UTR) into a luciferase
reporter vector then transfecting 293 T cells with the wt or
mt 3’UTR vector and miR-1 mimic or inhibitor (Figure 6A).
A significant decrease of luciferase activity was detected in
wt vectors after transfected with miR-1 mimic. A mutation
in the putative binding site in the Lasp1 3’UTR region
abrogated this repression, thereby providing additional
evidence of direct interaction between miR-1 and 3’UTR
region of Lasp1 (Figure 6B). mRNA expression by both
miR-1 and LASP1 was analysed by qRT-PCR in CRC tis-
sue samples. LASP1 mRNA levels in CRC tissues had a
negative correlation with miR-1 (Figure 6C). The result
was confirmed further during our investigation of miR-1
for its ability to suppress LASP1 mRNA and protein ex-
pression in CRC cells (Figure 6D).
To determine whether LASP1 rescue the suppressive ef-
fect of miR-1, we simultaneously co-transfected SW480
cells with miR-1 mimic and pcDNA3-LASP1 vector
(which contained all but the 3’UTR of LASP1) (Figure 6E).
We found that the ectopic expression of LASP1 partly
neutralized down-regulation of miR-1 on LASP1 expres-
sion and rescued miR-1-mediated inhibition of cell prolif-
eration and migration (Figure 6F-G).
Discussion
The expression of miRNAs was abnomal in various kinds
of human cancer [25,26]. More and more researches has
documented that miRNAs play essential roles in multiple
biological processes, including cell differentiation, pro-
liferation, angiogenesis, invasion and migration [27-30].
Recently, several studies have showed the deregulation
of miR-1 in many types of tumor, such as hepatocellular[12], prostate [13,14], thyroid [15], bladder [16] and renal
[17] cancer. In colorectal cancer, genome-wide profiling
of chromatin signatures reveals epigenetic regulation of
microRNA genes, and showed that miR-1 was methylated
frequently in early and advanced colorectal cancer in which
it may act as a tumor suppressor [19]. Our data demon-
strated that down-regulation of miR-1 was frequently exist
in CRC tissue and cell lines, suggesting a tumor suppressive
role of miR-1 in CRC development.
Until now, no functional evidence in vivo of miR-1 has
been documented in CRC. In prostate cancer, miR-1
inhibited cell proliferation, migration and invasion by
suppressing the expression of purine nucleoside phos-
phorylase (PNP) [14]. A follow-up study showed that
miR-1 was reduced in patients with distant metastasis
and recurrence, and may further serve as an independent
prognostic factor [13]. A recent study in vitro identified
that concomitant downregulation of miR-1 and increase of
metastasis-associated in colon cancer 1 (MACC1) can con-
tribute to MET overexpression and to the metastatic be-
havior of colon cancer cells [20]. Similarly, our gain- and
loss-of-function assay showed that miR-1 suppressed cell
proliferation and migration in vitro. Importantly, our find-
ings showed that miR-1 reduced tumor growth and
metastasis in vivo, suggesting its suppressive role in
CRC progression.
The molecular mechanisms underlying miR-1-mediated
biological behaviors are still unclear. To comprehensively
understand the effect of miR-1 on cancer cells, we per-
formed proteomic analysis to screen the alteration of pro-
tein profiling in CRC cells. Using 2-D DIGE, we found a
set of proteins that might be directly or indirectly modu-
lated by miR-1. The candidate proteins have been re-
ported involved in tumor development and progression.
Interestingly, our previous study has demonstrated that a
candidate protein, ARHGDIA, was upregulated in meta-
static CRC and promoted cell migration of CRC cells [31].
Another candidate protein, identified as TAGLN, has
been demonstrated as a potential target of miR-1 using
TargetScan software. Similarly, TAGLN2 has been re-
ported as a target of miR-1 in renal cell carcinoma [17],
bladder cancer [16] and head and neck squamous cell car-
cinoma [32]. These findings are consistent with our prote-
omic results and a suppressive role of miR-1 in CRC.
Epithelial–mesenchymal transition (EMT) plays a piv-
otal role in the initiation of metastasis, a process in which
Figure 6 LASP1 was a direct target of miR-1 in CRC cells. (A) Diagram of LASP1 3’UTR containing 2 putative conserved target sites for miR-1,
which were identified using the TargetScan database. (B) Results of luciferase reporter assays in 293 T cells, with cotransfection of wt or mt 3’UTR
and miR mimic and inhibitor, as indicated. (C) Expression of miR-1 and LASP1 mRNA were detected in CRC tissues by qRT-PCR analysis. A statistically
significant inverse correlation between miR-1 and LASP1 mRNA was observed in CRC specimens. (D) LASP1 protein expression in SW480, SW620, and
HCT116 cells 48 hours after transfection with miR-1 or anti-miR-1 was detected by Western blot analysis. The immunosignal was quantified
using densitometric scanning software, and relative protein abundance was determined by normalization with β-actin. Each bar represents
the mean ± SD. The results were reproduced in 3 independent experiments. The asterisk (*) indicates P < 0.05. (E) SW480 cells transfected
with miR-1 mimic and/or LASP1 cDNA were used to determine the role of LASP1 in miR-1–mediated biological behaviors. Expression of
LASP1 protein was detected by Western blot analysis. (F) Cell proliferation was determined by CCK-8 assay. (G) Results of transwell assay,
which was carried out to evaluate the effect of cell migration after transfection are shown.
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concomitant with a gain of mesenchymal components and
the initiation of a migratory phenotype [33,34]. Because the
effect of miR-1 on cell migration and gene expression regu-
lation, we detected the change of EMT markers in SW480
cells transfected with miR-1. The results supported that
miR-1 may reverse EMT process to inhibit cell migration.
Similarly, miRNA-1 suppresses prostate cancer metas-
tasis by regulating epithelial-mesenchymal transition
[35]. Further study showed that Slug is a major regu-
lator of mesenchymal differentiation and directly re-
presses miR-1 transcription. Slug and miR-1/-200 act
in a self-reinforcing regulatory loop, leading to ampli-
fication of EMT.
Our proteomic analysis revealed that miR-1 might be
associated with cell signaling pathway. The findings of
immunoblot assays demonstrated that miR-1 inactivated
MAPK/ERK and PI3K/AKT pathway by dephosphoryla-
tion of ERK1/2 and AKT, which is classical signal trans-
duction pathway and plays an essential role in tumor
progression. Recent researches revealed that the activa-
tion of cap-dependent translation by cooperative ERK
and AKT signaling is critical for promotion of CRC mo-
tility and metastasis. Inhibition of either ERK or AKT
alone showed limited activity in inhibiting cell migration
and invasion, but combined inhibition resulted in sig-
nificant impact [36]. To the best of its knowledge, we
firstly demonstrated miR-1 exerted its biological func-
tions by regulation of MAPK/ERK and PI3K/AKT path-
way, which may also explain miR-1-mediated reversion of
EMT process.
miRNAs generally exert their biological function by
suppressing their specific target genes at a posttranscrip-
tional level. A number of mRNAs were reported as dir-
ect targets of miR-1, such as transgelin 2 (TAGLN2)
[16,32], purine nucleoside phosphorylase (PNP) [14,32],
coding for the cyclin D2 (CCND2), CXC chemokine re-
ceptor 4 (CXCR4), stromal cell derived factor-1 (SDF-1)
[15], endothelin-1 [12] and fibronectin1 [37] et al. In the
research, we validated the targeting of LASP1 (a tumor
metastasis-associated protein in CRC), showing that
miR-1 may suppress tumors by binding directly in the
LASP1 3’UTR. LASP1 is a specific focal adhesion pro-
tein involved in numerous biological and pathological
processes [38,39]. Overexpression of LASP1 has been
described in several types of cancers [40-42]. In a previous
study, we demonstrated overexpression of LASP1 in meta-
static CRC tissue and found that the expression of this pro-
tein correlated closely with the overall survival of patients
with CRC. RNA interference-mediated silencing of LASP1
in SW620 CRC cells inhibited cell proliferation and migra-
tion significantly. However, gene transfection-mediated
overexpression of LASP1 in SW480 CRC cells resulted in
aggressive cancer cell phenotypes and promoted cancergrowth and metastasis (in contrast with the phenotypes
induced by miR-1 restoration). These results show that
LASP1 might be a promising target in developing treat-
ments for patients with CRC [10]. LASP1 overexpression
can rescue miR-1-mediated biological activity. These
results suggest that the inhibitory effect of miR-1 on
the biological activity and MAPK or AKT signal pathway
is mediated in part through the repression of LASP1
expression.
Taken together, the identification of miR-1 as a tumor-
suppressive miRNA in human CRC that acts by repressing
LASP1 provides x evidence of a pivotal role for miRNAs
in CRC tumorigenesis and progression. Given that miR-1
is down-regulated in CRC, the re-introduction of this ma-
ture miRNA into tumor tissue could serve as a thera-
peutic strategy by reducing the expression of target genes.
miRNA-based therapeutics are still in their infancy; how-
ever, our findings are encouraging and suggest that this
miRNA could be targeted for the development of a treat-
ment for patients with CRC, especially metastatic CRC, in
the future.
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